What adjuvant chemotherapy regimen is appropriate for a 70‑year‑old woman with a T2 hormone‑receptor‑positive, HER2‑negative breast cancer, one positive lymph node with extranodal extension after a modified radical mastectomy, and how should it be tailored to her age and tolerance?

Adjuvant Chemotherapy for a 70-Year-Old with T2, HR+/HER2- Breast Cancer and Node-Positive Disease

For this 70-year-old woman with T2, hormone receptor-positive, HER2-negative breast cancer with one positive lymph node and extranodal extension, adjuvant chemotherapy should be considered based on comprehensive geriatric assessment and genomic testing, but endocrine therapy remains the cornerstone of treatment regardless of chemotherapy decision.

Key Treatment Principles

Endocrine Therapy is Essential

• All patients with HR+/HER2- breast cancer should receive adjuvant endocrine therapy 1
• For node-positive disease, extended aromatase inhibitor (AI) therapy for up to 10 years total should be offered 1
• Options include:
  • AI for 5 years, then consider extending to 10 years total 1
  • Tamoxifen for 2-3 years, then switch to AI for up to 5 years (total 7-8 years) 1
  • Tamoxifen for 5 years, then switch to AI for up to 5 years (total 10 years) 1

Chemotherapy Decision-Making in Older Adults

The critical question is whether to add chemotherapy to endocrine therapy. This decision requires:

1. Geriatric Assessment

• Older adults (≥65 years) with breast cancer derive similar disease-free survival and overall survival benefits from adjuvant chemotherapy compared to younger patients, but have increased risk of side effects and treatment-related mortality 2
• Biologic age matters more than chronologic age—assess comorbidities, functional status, and life expectancy 2

2. Genomic Testing to Guide Chemotherapy

For node-positive, HR+/HER2- disease, the 21-gene recurrence score (Oncotype DX) is critical for decision-making:

• Recurrence Score (RS) <18: The 5-year risk of distant recurrence with endocrine therapy alone is only 2.7%, suggesting minimal absolute benefit from chemotherapy 3, 4
• RS ≥31: Clear benefit from adding chemotherapy to endocrine therapy 3, 4
• RS 11-25: Benefits are less clear in node-positive disease; consider patient age, tolerance, and preferences 3

In the absence of genomic testing, traditional high-risk features guide decisions: T2 tumor with extranodal extension suggests intermediate-to-high risk 5, 3

Recommended Chemotherapy Regimens if Indicated

If chemotherapy is pursued, age-appropriate regimens should be selected:

Preferred Regimens for Older Adults:

• TC (docetaxel/cyclophosphamide) × 4 cycles: Non-anthracycline option with improved disease-free survival and overall survival, potentially better tolerated 5, 6
• AC (doxorubicin/cyclophosphamide) × 4 cycles: Standard anthracycline-based option 5, 6

Important Caveats for Age 70:

• Single-agent capecitabine is inferior to CMF or AC and should be avoided 2
• Weekly docetaxel did not improve disease-free survival compared to CMF in older women (65-79 years) and was associated with severe toxicity and worse quality of life 2
• Dose-dense regimens may be more toxic in older adults—standard 3-week schedules are reasonable 5, 6

Treatment Sequencing

• Chemotherapy should be given before endocrine therapy (sequential, not concurrent) 5, 7
• Radiation therapy, if indicated, should follow chemotherapy completion 5, 7

Clinical Algorithm

Step 1: Obtain 21-gene recurrence score (Oncotype DX) if available 3, 4

Step 2: Perform comprehensive geriatric assessment 2

Step 3: Decision pathway:

• RS <18 OR frail/limited life expectancy (<5 years): Endocrine therapy alone 3, 2, 8
• RS ≥31 AND fit for chemotherapy: TC × 4 or AC × 4 followed by extended endocrine therapy 5, 3, 6
• RS 11-25 OR no genomic testing available: Shared decision-making weighing:
  • High-risk features (T2, extranodal extension) favor chemotherapy 5, 3
  • Age 70 and comorbidities favor endocrine therapy alone 2, 8
  • Patient preferences regarding toxicity vs. potential benefit 1, 2

Step 4: Regardless of chemotherapy decision, initiate extended endocrine therapy (AI preferred for node-positive disease) 1

Common Pitfalls

• Avoid assuming age 70 automatically excludes chemotherapy benefit—fit older adults derive similar relative benefits as younger patients 2, 9
• Do not use single-agent capecitabine or weekly docetaxel as standard adjuvant therapy in this population 2
• Extranodal extension is a high-risk feature that should not be dismissed—it increases recurrence risk 5
• Extended endocrine therapy (up to 10 years) is strongly recommended for node-positive disease regardless of chemotherapy use 1
• Treatment-related mortality is higher in older adults (0.5% overall, higher in elderly)—cardiac function and comorbidities must be assessed 9